PolygenRx Pty Ltd
PolygenRx has established a ‘first in class digital platform’ for reducing the cost and risk of clinical stage drug development by capturing each individual’s unique constellation of clinically actionable genetic…
Services
- Genetically guided pharmaceutical responder enrichment
- Causal modelling of drug targets
Overview
PolygenRx has established a ‘first in class digital platform’ for reducing the cost and risk of clinical stage drug development by capturing each individual’s unique constellation of clinically actionable genetic variation to inform treatment options and decisions. It’s essentially a personalised matchmaker for pairing drugs with disease.
This enables selection and enrichment of responders during and after drug development. We are using this highly scalable approach to identify new treatments, accelerate drug development, and implement precision medicine.
Our pipeline of clinical stage assets, spanning a broad range of indications from psychiatric, neurological, inflammatory, fibrotic, and cardiovascular diseases, are ready for phase III clinical trial.
We are also offering our capability to prioritise and accelerate the development of pharmaceutical company assets though the genetic enrichment for clinical responders. This enables targeted participant selection for clinical trial that reduces cost, risk and time to market.
We can proactively generate companion diagnostics to support targeted therapy during drug development or generate complementary diagnostics for use as a regulated in vitro device to support post-market treatment decisions in approved medications.
Our transformative technology is a game changer for the treatment of chronic disease enabling every drug to reach its full potential.
Delegates
